FE, ETRFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment. The drug, SSGJ-707, is currently in clinical trials in China for use against lung, colorectal and gynaecological cancers. 